Article updated: 1/18/2013 3:59 PM

Lilly drug chosen for Alzheimer’s study

Buy this photo Buy this photo
Gallery Image

An Eli Lilly and Co. employee packages a drug at the Lilly USA facility in Indianapolis.

Associated Press file photo/2001

About this Article

In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease.